FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL

OMB Number: 3235-010

Estimated average burden hours per response: 0.5

or Section 30(h) of the Investment Company Act of 1940 2. Date of Event 3. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person* Requiring Statement Beam Therapeutics Inc. [BEAM] ARCH Venture Partners IX, LLC (Month/Day/Year) 02/05/2020 4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of Original Filed (Last) (Middle) (First) (Month/Day/Year) (Check all applicable) 8755 W. HIGGINS ROAD X 10% Owner Director **SUITE 1025** Officer (give title Other (specify 6. Individual or Joint/Group Filing (Check below) below) Applicable Line) Form filed by One Reporting Person (Street) Form filed by More than One **CHICAGO** IL60631 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial Ownership Beneficially Owned (Instr. 4) Form: Direct (D) or Indirect (I) (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 2. Date Exercisable and 1. Title of Derivative Security (Instr. 4) 3. Title and Amount of Securities 6. Nature of Indirect **Expiration Date Underlying Derivative Security (Instr. 4)** Conversion Ownership **Beneficial Ownership** (Month/Day/Year) or Exercise Form: (Instr. 5) Direct (D) Price of Amount or or Indirect Derivative Expiration Date Number of Security (I) (Instr. 5) Exercisable Date Shares Title See footnote⁽¹⁾ (2) (2) Series A-1 Preferred Stock Common Stock 1,338,000 Ι Series A-1 Preferred Stock (2) (2) Common Stock 1,338,000 (2) Ι See footnote⁽³⁾ (2) Series A-2 Preferred Stock (2) Common Stock 2,750,336 Ι See footnote(1) (2) (2) (2) Series A-2 Preferred Stock Common Stock 2,750,335 T See footnote⁽³⁾ (2) Series B Preferred Stock (2) (2) I See footnote(1) Common Stock 33,184 Series B Preferred Stock (2) (2) Common Stock 33,184 (2) See footnote⁽³⁾

1. Name and Address of Reporting Person* ARCH Venture Partners IX, LLC			
(Last)	(First)	(Middle)	
8755 W. HIGGINS ROAD			
SUITE 1025			
(Street)			
CHICAGO	IL	60631	
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person* ARCH Venture Partners IX, L.P.			
(Last)	(First)	(Middle)	
8755 W. HIGGINS ROAD			
SUITE 1025			
(Street)			
CHICAGO	IL	60631	
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			

ARCH Venture Partners IX Overage, L.P.

(Last)	(First)	(Middle)		
8755 W. HIGGINS	ROAD			
SUITE 1025				
(Street)				
CHICAGO	IL	60631		
(City)	(State)	(Zip)		
1. Name and Address of Reporting Person* ARCH Venture Fund IX, L.P.				
(Last)	(First)	(Middle)		
8755 W. HIGGINS		,		
SUITE 1025				
(0)				
(Street) CHICAGO	IL	60631		
(City)	(State)	(Zip)		
1. Name and Address	of Reporting Person*			
ARCH Venture Fund IX Overage, L.P.				
(Last)	(First)	(Middle)		
8755 W. HIGGINS	S ROAD			
SUITE 1025				
(Street) CHICAGO	IL	60631		
(City)	(State)	(Zip)		
Name and Address of Reporting Person* CRANDELL KEITH				
(Last)	(First)	(Middle)		
C/O ARCH VENT	URE PARTNERS IX	, LLC		
8755 W. HIGGINS ROAD SUITE 1025				
(Stroot)				
(Street) CHICAGO	IL	60631		
(City)	(State)	(Zip)		
1. Name and Address	of Reporting Person*			
BYBEE CLIN	BYBEE CLINTON			
(Last)	(First)	(Middle)		
C/O ARCH VENT	URE PARTNERS IX	, LLC		
8755 W. HIGGINS ROAD SUITE 1025				
(Street) CHICAGO	IL	60631		

Explanation of Responses:

(State)

(Zip)

Remarks:

(City)

^{1.} These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

^{2.} Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the registrant, for no additional consideration. There is no expiration date for the Preferred Stock.

^{3.} These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Fact for Robert Nelsen, Managing Director

By: ARCH Venture Partners
IX I. P. By: ARCH Venture

IX, L.P., By: ARCH Venture
Partners IX, LLC, its General

Partner, By: /s/ Mark 02/05/2020

McDonnell, as Attorney-in-

Fact for Keith Crandell, Managing Director

By: ARCH Venture Partners IX

Overage, L.P., By: ARCH Venture Partners IX, LLC, its

General Partner, By: /s/ Mark 02/05/2020

McDonnell, as Attorney-in-

Fact for Keith Crandell,

Managing Director

By: ARCH Venture Fund IX,

L.P., By: ARCH Venture

Partners IX, L.P., its General

Partner, By: ARCH Venture

Partners IX, LLC, its General 02/05/2020

Partner, By: /s/ Mark

McDonnell, as Attorney-in-

Fact for Keith Crandell,

Managing Director

By: ARCH Venture Fund IX

Overage, L.P., By: ARCH

Venture Partners IX Overage,

L.P., its General Partner, By:

ARCH Venture Partners IX, 02/05/2020

LLC, its General Partner, By:

/s/ Mark McDonnell, as

Attorney-in-Fact for Keith

Crandell, Managing Director

By: Keith Crandell, Managing

Director, By: /s/ Mark

McDonnell, as Attorney-in-

Fact

By: Clinton Bybee, Managing

Director, By: /s/ Mark

McDonnell, as Attorney-in-

Fact

** Signature of Reporting Person

Date

02/05/2020

02/05/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

POWERS OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his or its true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of January, 2019.

ARCH VENTURE FUND IX, L.P.

By: ARCH Venture Partners IX, L.P. its General Partner

By: ARCH Venture Partners IX, LLC its General Partner

By: /s/Keith Crandell
-----Managing Director

ARCH VENTURE PARTNERS IX, L.P.

By: ARCH Venture Partners IX, LLC its General Partner

By: /s/Keith Crandell
-----Managing Director

ARCH VENTURE FUND IX OVERAGE, L.P.

By: ARCH Venture Partners IX Overage, L.P. its General Partner

By: ARCH Venture Partners IX, LLC its General Partner

By: /s/Keith Crandell

Managing Director

ARCH VENTURE PARTNERS IX OVERAGE, L.P.

By: ARCH Venture Partners IX, LLC its General Partner

By: /s/Keith Crandell
----Managing Director

ARCH VENTURE PARTNERS IX, LLC

By: /s/Robert Nelsen
Managing Director

/s/Keith Crandell -----Keith Crandell /s/Kristina Burow ------Kristina Burow

/s/Clint Bybee -----Clint Bybee

/s/Robert Nelsen ------Robert Nelsen